百奥泰发布业绩快报，2025年度实现营业收入9.34亿元，同比增长25.64%；净利润亏损3.36亿元，上年 同期亏损5.1亿元。报告期内，公司积极拓展市场，阿达木单抗注射液（格乐立 ）和托珠单抗注射液 （施瑞立 ）销售额较上年同期稳步提升。本报告期公司乌司奴单抗注射液（STARJEMZA ）于美国上 市销售，授权许可收入及销售收入增长。 ...

Core Viewpoint - Baotai (688177) is expected to reduce its losses in 2025, projecting a net profit attributable to shareholders of between -280 million to -390 million yuan, a decrease in losses of 120 million to 230 million yuan compared to the previous year [1] Financial Performance - The company anticipates revenue between 900 million to 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] - The sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shilili) have steadily increased compared to the previous year [1] Market Expansion - The launch of Ustekinumab injection (STARJEMZA) in the United States has contributed to growth in both licensing income and sales revenue [1]